A5053802334- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Immunotherapy and Immune Responses
- Urinary Bladder and Prostate Research
- Virus-based gene therapy research
- Multiple and Secondary Primary Cancers
- Pelvic floor disorders treatments
- Urologic and reproductive health conditions
- Hormonal and reproductive studies
- Cancer Research and Treatments
- Renal and related cancers
- Ureteral procedures and complications
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Organ Donation and Transplantation
- Esophageal Cancer Research and Treatment
- Kidney Stones and Urolithiasis Treatments
- Renal and Vascular Pathologies
- Pediatric Urology and Nephrology Studies
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
Ehime University
2017-2025
Ehime University Hospital
2023-2024
Ebara (Japan)
2018
Obayashi (Japan)
2018
Okayama University
2004-2014
Citizens Specialty Hospitals
2014
Hiroshima City Asa Citizens Hospital
2014
Okayama University Hospital
2008-2012
City Hospital
2012
Okayama Medical Center
2012
Neuroendocrine prostate carcinoma (NEPC) accounts for less than 1% of neoplasms and has extremely poorer prognosis the typical androgen receptor pathway-positive adenocarcinoma (ARPC). However, very few cases in which de novo NEPC APRC are diagnosed simultaneously same tissue have been reported. We report herein a 78-year-old man metastatic coexisting with ARPC treated at Ehime University Hospital. Visium CytAssist Spatial Gene Expression analysis (10× genetics) was performed using...
We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as first prostate cancer therapy trial. Major inclusion criteria were local recurrence after hormonal and no metastasis. Adv.HSV-tk injected directly into escalating doses from 109 to 1010 infection units, followed intravenous administration GCV for 14 days. Eight patients received nine courses this therapy. The detection...
Serological expression cloning of antigens eliciting a humoral immune response to syngeneic mouse sarcoma identified pem (mouse placenta and embryonic gene) as new member the cancer/testis family. To identify human homologue , sequences -related expressed sequence tags from testis were used PCR primers for amplification using cDNA. However, rather than another gene, designated OY-TES-1 was isolated found be proacrosin binding protein sp32 precursor originally in mouse, guinea pig, pig. maps...
Prostate-specific membrane antigen (PSMA) protein expression is induced during prostate cancer progression and metastasis. Recently, we reported that PSMA-positive vesicles released by cell lines enhanced vascular endothelial angiogenesis PSMA may be involved in tumor angiogenesis. Similarly, it known upregulated peritumoral vessels renal carcinoma (RCC). In this study, investigated the significance molecular function of RCC. immunohistochemical staining confirmed presence only perinephric...
Abstract Objective To evaluate the real-world clinical usage and effectiveness of apalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods We retrospectively reviewed data 186 who received across 17 institutions. The primary outcomes were for nmCRPC: prior other androgen receptor signaling inhibitors (ARSIs), radical treatment, distribution prostate-specific antigen (PSA) doubling time (PSA-DT) at initial administration apalutamide. secondary efficacy...
The therapeutic efficacy of extended lymph node dissection (ePLND) for intermediate- and high-risk (IR/HR) prostate cancer remains controversial. This study evaluated whether PLND improved biochemical recurrence (BCR) rates in patients with undergoing robotic-assisted radical prostatectomy (RARP) using a propensity matching method cases from two facilities. included 1002 IR/HR disease who underwent RARP at facilities equivalent surgical techniques hospital size but different ePLND policies...
561 Background: The expression of prostate-specific membrane antigen (PSMA) protein increases as prostate cancer advances and metastasizes. Recently, 68Ga-labeled PSMA PET has been used in diagnosing cancer. Our previous studies demonstrated that PSMA-positive vesicles secreted by cells enhance the angiogenic activity vascular endothelial cells, suggesting a role for tumor angiogenesis. In this study, we focus on renal cell carcinoma, examining relationship between peritumoral blood vessels...
ABSTRACT Renal pelvic carcinoma in a horseshoe kidney is rare, and reports on robotic surgery for this condition are limited. We present case of 64‐year‐old male diagnosed with right renal kidney. The patient underwent robot‐assisted radical nephroureterectomy using the da Vinci Xi surgical system, preoperative anatomical visualization enhanced by 3D imaging software (SYNAPSE VINCENT). total operative time was 6 h 31 min, blood loss 185 mL. procedure completed without complications....
Abstract Introduction In order to elucidate the influence of hormone‐releasing hormone (LH‐RH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long‐term LH‐RH 10 therapy. Patients Methods A consecutive 32 had over 24 months were enrolled. As a baseline, T LH measured at time cessation, monthly for 3 months,...
NY-ESO-1 specific humoral responses are frequently observed in patients with various types of antigen expressing tumors. In a large proportion antibody-positive NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring the immune response may relevant and more practical surrogate for estimating overall against clinical vaccine studies. We have immunized 9 cancer full length protein formulated cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) investigated NY-ESO-1....
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To explore whether levels nerve growth factor (NGF) in expressed prostatic secretions (EPS) are correlated with symptom severity chronic prostatitis (CP) and pelvic pain syndrome (CPPS). PATIENTS AND METHODS All patients CP/CPPS underwent a complete history physical examination, were scored according to the National Institutes Health Chronic Prostatitis Symptom Index (NIH‐CPSI). Expressed secretion samples from 20 four...